secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-10-20T13:37:52+00:00
Accession:  0001129928-26-000074
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Oncolytics ESMO abstract details 60-patient REO 033 colorectal study; prior REO 022 showed 17-month PFS vs 6
--------------------------------------------------------------------------------

- REO 033 randomized, open-label Phase 2 study enrolls 30 patients per arm: pelareorep + FOLFIRI + bevacizumab vs FOLFIRI + bevacizumab in 2L RAS-mutant MSS mCRC.
- Primary endpoint is objective response rate; secondary endpoints include OS, PFS, disease control rate, duration of response, safety/tolerability, and biomarker sampling.
- Recent FDA interactions enable pivotal Part B expansion of REO 033, potentially supporting accelerated approval based on ORR and full approval based on PFS.
- Prior REO 022 in 2L KRAS-mutant MSS mCRC more than doubled ORR, median PFS, OS and DOR versus historical FOLFIRI/bevacizumab; headline cites 17-month PFS vs 6 months.
- Abstract 994eTiP e-poster at ESMO Congress 2026; lead investigator Sanjay Goel cited conviction pelareorep can meaningfully impact patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000074/0001129928-26-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000074/oncy-20261020.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer